The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Socioeconomic factors and outcomes among patients with recurrent/metastatic head and neck cancer receiving immunotherapy.
 
Natalie F. Uy
No Relationships to Disclose
 
Kevin Ng
No Relationships to Disclose
 
Jenna M. Voutsinas
No Relationships to Disclose
 
Vicky Wu
No Relationships to Disclose
 
Cristina Maria Merkhofer
Research Funding - Merck
 
Diane Tseng
Stock and Other Ownership Interests - Forty Seven
Patents, Royalties, Other Intellectual Property - Use of Anti-CD47 Agents to Enhance Immunization. Provisional Application to U.S. Patent and Trademark Office.
 
Nicholas Peter Giustini
Honoraria - Curio Science; OMNI Health Media; OMNI Health Media
 
Sylvia Lee
Research Funding - Bristol-Myers Squibb; Iovance Biotherapeutics; Kite, a Gilead Company; PACT Pharmaceuticals; Seagen
Patents, Royalties, Other Intellectual Property - Patent licensed to Lyell
 
Christina S Baik
Consulting or Advisory Role - AstraZeneca; Blueprint Medicines; Daiichi; Guardant Health; Regeneron; Silverback Therapeutics; Takeda; Turning Point Therapeutics
Research Funding - Abbvie (Inst); AstraZeneca (Inst); Blueprint Medicines (Inst); Daiichi Sankyo (Inst); Janssen (Inst); Lilly (Inst); Loxo (Inst); Pfizer (Inst); Rain Therapeutics (Inst); Spectrum Pharmaceuticals (Inst); TP Therapeutics (Inst)
 
Rafael Santana-Davila
Consulting or Advisory Role - AstraZeneca; EMD Serono; Jazz Pharmaceuticals; Mirati Therapeutics; Takeda Science Foundation
Research Funding - ALX Oncology (Inst); BeyondSpring Pharmaceuticals (Inst); Genentech (Inst); ISA Pharmaceuticals (Inst); Lilly (Inst); Merck (Inst); Pfizer (Inst)
 
Keith D. Eaton
Consulting or Advisory Role - Lilly
Research Funding - Mirati Therapeutics (Inst)
 
Cristina P. Rodriguez
Consulting or Advisory Role - Abbvie (I); ADC Therapeutics (I); AstraZeneca (I); beigene (I); Coherus Biosciences; Incyte (I); Karyopharm Therapeutics (I); Kite, a Gilead company (I); Millenium Pharamceuticals (I); Millenium Pharamceuticals (I)
Research Funding - AstraZeneca/MedImmune (Inst); Ayala Pharmaceuticals (Inst); Bayer (Inst); BeiGene (Inst); Bristol-Myers Squibb (Inst); CUE Biopharma (Inst); Denovo Biopharma (Inst); Genentech (Inst); Ignyta (Inst); Incyte (Inst); Kura Oncology (Inst); Merck (Inst)